LDS/Medical Tests/Oxazepam, Urine

Oxazepam, Urine

Oxazepam belongs to the class of drugs known as Benzodiazepines. The benzodiazepines are a class of medications (drugs) that produce the following effects: sedation and anxiety relief. They are one of the most widely prescribed drugs in the world. Benzodiazepines have essentially replaced the use of barbiturates as the major class of CNS depressants.

Oxazepam is an intermediate-acting benzodiazepine and is primarily used to treat anxiety, and is an adjunct in dealing with patients going through alcohol withdrawal. Following an oral dose it is well absorbed with a bioavailability of about 95%.

Oxazepam is not extensively metabolized and exists in the urine as oxazepam glucuronide. Oxazepam is the slowest of the benzodiazepines to be absorbed; therefore, the onset of oxazepam’s therapeutic effect is also slow.

Oxazepam is one of the benzodiazepine classes that are typically used by drug abusers. Long-term abuse can lead to respiratory depression or in severe cases, coma. Benzodiazepines are frequently abused drugs and associated especially with heroin and cocaine abusers. Benzodiazepines are only legally available through prescription. Many abusers obtain their supply of these drugs by acquiring several prescriptions from several different physicians, or by forging prescriptions, or by obtaining them illicitly.

Benzodiazepines are rapidly metabolized and excreted into the urine, allowing detection by various methods such as Gas Chromatography/Mass Spectroscopy (GC/MS), Liquid Chromatography/Mass Spectroscopy (LC/MS), Immunoassay (IA) screening, and screening spot testing.

Benzodiazepines can elicit the following side effects: amnesia, hostility, irritability, skin rash, allergic reactions and vivid or disturbing dreams. Overdose effects include shallow respiration, clammy skin, dilated pupils, weak and rapid pulse, coma, and possible death. 

  • Therapeutic monitoring in serum
  • Drug abuse evaluation
  • Toxicity assessment in serum
  • Patient Compliance
Any qualitative positive result from an immunoassay (IA) screening type test indicates only the presence of any benzodiazepine such as Oxazepam and is not specific and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as GC, LC/MS, or GC/MS.

Therapeutic concentration: 200-500 ng/mL
Toxic concentration: >2000 ng/mL
Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

Cut-Off Ranges
Cut-Off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection whether it is a qualitative method such as immunoassay, or a quantitative method, such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

Liquid Chromatography/Mass Spectroscopy (LC/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), or Immunoassay (IA). The main method of quantification is via LC/MS. This particular method of analysis is used to detect the parent drug compound, oxazepam. Oxazepam, as well as all benzodiazepines, can be separated from biological specimens by liquid-liquid extraction or by solid-phase extraction. When analyzing urine specimens a hydrolysis step may be required to free the parent drug and metabolites from glucuronide conjugates. Enzymatic hydrolysis is preferred over acid hydrolysis, since some benzodiazepines are unstable in acid medium and rearrange to form benzophenones.

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3-5 days
  • Refrigeration: 7-14 days
  • Frozen: 30 days
Pain drug management pharmacogenomics panel or CYP3A4, CYP2C19 may be tested for drug safety and efficacy before prescribing. Supportive testing such as Liver profile, Kidney profile, Comprehensive Metabolic Panel, CBC (if overdose), other drugs if necessary.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Addict Dis. 2010 Oct;29(4):436-48. [PMID: 20924879]
  • Ann Clin Biochem. 1997 Sep;34 ( Pt 5):460-510. [PMID: 9293303]
  • Cochrane Database Syst Rev. 2012 Jul 11;7:CD007139. [PMID: 22786504]
  • Eur J Drug Metab Pharmacokinet. 1982;7(3):191-6. [PMID: 7173273]
  • Principles of Forensic Toxicology, Fourth Edition. Ed, Barry Levine. AACC Press, Washington DC. Chapter 14, Benzodiazepines, pp. 237-251, (2013).
  • Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, Eds. Goodman and Gilman’s the Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill Co. (1996).
  • Baselt RC, Ed. Disposition of Toxic Drugs and Chemicals in Man, 6th ed. Foster City, CA: Biomedical Publications (2002).
  • Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7): 169-79
  • Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4): 7-20.